Thermo Fisher Scientific (TMO) Expected to Post Earnings on Wednesday

Thermo Fisher Scientific (NYSE:TMO) is projected to issue its Q3 2026 results before the market opens on Wednesday, October 21st. Analysts expect the company to post earnings of $6.40 per share and revenue of $11.95 billion for the quarter. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Interested persons may review the information on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Wednesday, October 21, 2026 at 7:00 AM ET.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%. The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the previous year, the business earned $4.28 EPS. The company’s quarterly revenue was up 10.5% on a year-over-year basis. On average, analysts expect Thermo Fisher Scientific to post $25.13 EPS for the current fiscal year and $27.53 EPS for the next fiscal year.

Thermo Fisher Scientific Stock Up 0.0%

TMO stock opened at $690.22 on Monday. The stock’s 50 day moving average is $637.32 and its 200-day moving average is $548.58. Thermo Fisher Scientific has a twelve month low of $435.27 and a twelve month high of $704.00. The firm has a market capitalization of $255.20 billion, a PE ratio of 37.13, a P/E/G ratio of 2.89 and a beta of 0.87. The company has a quick ratio of 1.18, a current ratio of 1.55 and a debt-to-equity ratio of 0.74.

Analysts Set New Price Targets

A number of equities analysts have issued reports on TMO shares. Guggenheim assumed coverage on shares of Thermo Fisher Scientific in a report on Thursday. They set a “buy” rating on the stock. HSBC raised shares of Thermo Fisher Scientific from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 1st. Jefferies Financial Group restated a “buy” rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, July 23rd. Royal Bank Of Canada set a $740.00 price objective on shares of Thermo Fisher Scientific in a research report on Thursday. Finally, Weiss Ratings upgraded shares of Thermo Fisher Scientific from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, three have given a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $654.05.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, CAO Joseph R. Holmes sold 420 shares of the company’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the transaction, the chief accounting officer owned 2,966 shares of the company’s stock, valued at $1,734,546.46. This represents a 12.40% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the sale, the chief executive officer directly owned 123,925 shares of the company’s stock, valued at approximately $77,982,284.75. This trade represents a 7.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 73,768 shares of company stock valued at $44,122,820 in the last quarter. Insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific News Roundup

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Analysts expect third-quarter adjusted earnings of approximately $6.40 per share, with results likely to show whether Thermo Fisher’s growth is continuing into the second half of 2026. Thermo Fisher Scientific Q3 2026 Preview
• Positive Sentiment: Recent investor commentary cites strong operating results and a recovery in Thermo Fisher’s Life Sciences Solutions business, while academic and government research spending remain important sources of demand. Thermo Fisher Scientific Outperforms on Strong Results and Life Sciences Recovery Academic and Government Spending Powers Thermo Fisher
• Positive Sentiment: Thermo Fisher is positioned to benefit from growth in immuno-oncology diagnostics, a market forecast to reach $11.1 billion by 2030, although the opportunity is shared with competitors including Roche, Illumina and Agilent. Immuno-Oncology Diagnostics Market Forecast
• Neutral Sentiment: Analysts are also examining key metrics such as segment performance and margins for the September quarter; those details could determine whether the expected earnings growth is high quality. Analyst Projections for Thermo Fisher Key Metrics
• Negative Sentiment: Valuation concerns may be weighing on the shares. Thermo Fisher trades at a premium earnings multiple after a substantial advance and has reached a new 52-week high, prompting some analysts to maintain a cautious or “hold” view despite strong growth prospects. Thermo Fisher Strong Growth, Even Higher Stock Price

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.